Abstract
Most gene mutations associated with Alzheimers disease point to the metabolism of amyloid precursor protein as potential cause. The β- and γ-secretases are two executioners of amyloid precursor protein processing resulting in amyloid β. Significant progress has been made in the selective inhibition of both proteases, regardless of structural information for γ-secretase. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. This review focuses on the developments since 2003.
Keywords: Alzheimer's disease, secretase, aspartic protease, inhibitor, presenilin
Current Topics in Medicinal Chemistry
Title: Inhibitors and Modulators of β- and γ-Secretase
Volume: 6 Issue: 4
Author(s): Boris Schmidt, Stefanie Baumann, Hannes A. Braun and Gregor Larbig
Affiliation:
Keywords: Alzheimer's disease, secretase, aspartic protease, inhibitor, presenilin
Abstract: Most gene mutations associated with Alzheimers disease point to the metabolism of amyloid precursor protein as potential cause. The β- and γ-secretases are two executioners of amyloid precursor protein processing resulting in amyloid β. Significant progress has been made in the selective inhibition of both proteases, regardless of structural information for γ-secretase. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. This review focuses on the developments since 2003.
Export Options
About this article
Cite this article as:
Schmidt Boris, Baumann Stefanie, Braun A. Hannes and Larbig Gregor, Inhibitors and Modulators of β- and γ-Secretase, Current Topics in Medicinal Chemistry 2006; 6 (4) . https://dx.doi.org/10.2174/156802606776287027
DOI https://dx.doi.org/10.2174/156802606776287027 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Crocus Sativus</i> L. (Saffron) in Alzheimer’s Disease Treatment: Bioactive Effects on Cognitive Impairment
Current Neuropharmacology Non-steroidal Anti-inflammatory Drugs and Cyclooxygenase in Alzheimer s Disease
Current Drug Targets Association of rs610932 and rs670139 Polymorphisms in the MS4A Gene Cluster with Alzheimer’s Disease: An Updated Meta-analysis
Current Alzheimer Research Candidate Susceptibility Genes in Alzheimers Disease Are at High Risk for Being Forgotten - They Dont Give Peace of Mind...
Current Drug Metabolism An fMRI Stroop Task Study of Prefrontal Cortical Function in Normal Aging, Mild Cognitive Impairment, and Alzheimers Disease
Current Alzheimer Research Patented In Vitro Blood-Brain Barrier Models in CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Rheumatoid Arthritis and Cardiovascular Risk: Between Lights and Shadows
Current Rheumatology Reviews Non-Analgesic Effects of Opioids: The Cognitive Effects of Opioids in Chronic Pain of Malignant and Non-Malignant Origin. An Update.
Current Pharmaceutical Design Cardiac Effect of Cholinesterase Inhibitors Used in Alzheimers Disease - from Basic Research to Bedside
Current Alzheimer Research Small Molecule TGF-beta Mimetics as Potential Neuroprotective Factors
Current Alzheimer Research Maintaining Plasma Fibrinogen Levels and Fibrinogen Replacement Therapies for Treatment of Intracranial Hemorrhage
Current Drug Targets Functional and Structural MRI Biomarkers to Detect Pre-Clinical Neurodegeneration
Current Alzheimer Research A Simple High Efficiency Intra-Islet Transduction Protocol Using Lentiviral Vectors
Current Gene Therapy Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Functional Neuroimaging of Sleep Disorders
Current Pharmaceutical Design Limonin, A Citrus Limonoid, had no Apparent Effect on Cognitive Dysfunction in Mice with Chronic Cerebral Hypoperfusion
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Elucidating Neuronal and Vascular Injury Through the Cytoprotective Agent Nicotinamide
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives
Current Pharmaceutical Design